A phase III, multicenter, randomized, open labeled study to evaluate the immunogenicity, reactogenicity and safety of ROTAVAC 5CM of the live attenuated rotavirus vaccine as a 3 dose series when compared with existing ROTAVACÂ in healthy infants aged 6-8 weeks - ROTAVAC5CM
Latest Information Update: 03 Jul 2019
At a glance
- Drugs ORV 116E (Primary) ; Rotavirus vaccine
- Indications Rotavirus infections
- Focus Pharmacodynamics
- Sponsors Bharat Biotech
- 12 Nov 2018 Status changed from recruiting to completed.
- 28 Dec 2016 Status changed from not yet recruiting to recruiting.
- 13 Dec 2016 New trial record